Herein, we found that SERPINB3 is downregulated by HPV‐E6 and reverses the cisplatin resistance of HPV‐negative HNSCC by interfering with DNA damage repair of the FA pathway by inhibiting USP1, thereby providing a theoretical basis for clinical targeted therapy. This evidence concerns the gene SERPINB3 and head and neck squamous cell carcinoma.